Compare WHG & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | ARMP |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.2M | 199.7M |
| IPO Year | 2002 | 1996 |
| Metric | WHG | ARMP |
|---|---|---|
| Price | $18.53 | $3.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 7.2K | ★ 83.9K |
| Earning Date | 11-05-2026 | 11-24-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | ★ 203.85 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $97,762,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.41 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $14.70 | $2.75 |
| 52 Week High | $20.97 | $14.98 |
| Indicator | WHG | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 56.00 |
| Support Level | $15.70 | $3.38 |
| Resistance Level | $20.12 | $3.96 |
| Average True Range (ATR) | 0.53 | 0.36 |
| MACD | -0.03 | 0.11 |
| Stochastic Oscillator | 0.00 | 92.59 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.